Ewelina Litwinska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ewelina Litwinska has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Africa Pertierra Cortada
Neonatology Department, BCNatal—Centre de Medicina Maternofetal i Neonatologia de Barcelona, Hospital Sant Joan de Déu, Universitat de Barcelona, 08950 Barcelona, Spain
1 shared publication - Alexandra Benachi
Department of Obstetrics and Gynecology, Antoine Béclère Hospital, Paris Saclay University, AP-HP, Clamart, France
1 shared publication - Anne Debeer
Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium
1 shared publication - Anne-Gael Cordier
Department of Obstetrics and Reproductive Medicine Hôpital Tenon, APHP, Sorbonne University Paris France
1 shared publication Bartosz Polis
Department of Neurosurgery, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland
1 shared publication- David Basurto
Department of Development and Regeneration, Cluster Woman and Child, Biomedical Sciences, My FetUZ Fetal Research Center, KU Leuven, Leuven, Belgium
1 shared publication
Latest Publications
- 1 March 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 57 (3) , 378-385
Fetal endoscopic tracheal occlusion reverses the natural history of right‐sided congenital diaphragmatic hernia: European multicenter experience
Objective: To evaluate the neonatal outcome of fetuses with isolated right‐sided congenital diaphragmatic hernia (iRCDH) based on prenatal severity indicators and antenatal management. Methods: This was a retrospective review of prospectively collected data on consecutive cases diagnosed with iRCDH before 30 weeks' gestation in four fetal therapy centers, between January 2008 and December 2018. Data on prenatal severity assessment, antenatal management and perinatal outcome were retrieved. Univariate and multivariate logistic regression analysis were used to identify predictors of survival at discharge and early neonatal morbidity. Results: Of 265 patients assessed during the study period, we excluded 40 (15%) who underwent termination of pregnancy, two cases of unexplained fetal death, two that were lost to follow‐up, one for which antenatal assessment of lung hypoplasia was not available and six cases which were found to have major associated anomalies or syndromes after birth. Of the 214 fetuses with iRCDH included in the neonatal outcome analysis, 86 were managed expectantly during pregnancy and 128 underwent fetal endoscopic tracheal occlusion (FETO) with a balloon. In the expectant‐management group, lung size measured by ultrasound or by magnetic resonance imaging was the only independent predictor of survival (observed‐to‐expected lung‐to‐head ratio (o/e‐LHR) odds ratio (OR), 1.06 (95% CI, 1.02–1.11); P = 0.003). Until now, stratification for severe lung hypoplasia has been based on an o/e‐LHR cut‐off of 45%. In cases managed expectantly, the survival rate was 15% (4/27) in those with o/e‐LHR ≤ 45% and 61% (36/59) for o/e‐LHR > 45% ( P = 0.001). However, the best o/e‐LHR cut‐off for the prediction of survival at discharge was 50%, with a sensitivity of 78% and specificity of 72%. In the expectantly managed group, survivors with severe pulmonary hypoplasia stayed longer in the neonatal intensive care unit than did those with mildly hypoplastic lungs. In fetuses with an o/e‐LHR ≤ 45% treated with FETO, survival rate was higher than in those with similar lung size managed expectantly (49/120 (41%) vs 4/27 (15%); P = 0.014), despite higher prematurity rates (gestational age at birth: 34.4 ± 2.7 weeks vs 36.8 ± 3.0 weeks; P < 0.0001). In fetuses treated with FETO, gestational age at birth was the only predictor of survival (OR, 1.25 (95% CI, 1.04–1.50); P = 0.02). Conclusions: Antenatal measurement of lung size can predict survival in iRCDH. In fetuses with severe lung hypoplasia, FETO was associated with a significant increase in survival without an associated increase in neonatal morbidity. © 2020 International Society of Ultrasound in Obstetrics and Gynecology
- 1 March 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 57 (3) , 378-385
Fetal endoscopic tracheal occlusion reverses the natural history of right‐sided congenital diaphragmatic hernia: European multicenter experience
Objective: To evaluate the neonatal outcome of fetuses with isolated right‐sided congenital diaphragmatic hernia (iRCDH) based on prenatal severity indicators and antenatal management. Methods: This was a retrospective review of prospectively collected data on consecutive cases diagnosed with iRCDH before 30 weeks' gestation in four fetal therapy centers, between January 2008 and December 2018. Data on prenatal severity assessment, antenatal management and perinatal outcome were retrieved. Univariate and multivariate logistic regression analysis were used to identify predictors of survival at discharge and early neonatal morbidity. Results: Of 265 patients assessed during the study period, we excluded 40 (15%) who underwent termination of pregnancy, two cases of unexplained fetal death, two that were lost to follow‐up, one for which antenatal assessment of lung hypoplasia was not available and six cases which were found to have major associated anomalies or syndromes after birth. Of the 214 fetuses with iRCDH included in the neonatal outcome analysis, 86 were managed expectantly during pregnancy and 128 underwent fetal endoscopic tracheal occlusion (FETO) with a balloon. In the expectant‐management group, lung size measured by ultrasound or by magnetic resonance imaging was the only independent predictor of survival (observed‐to‐expected lung‐to‐head ratio (o/e‐LHR) odds ratio (OR), 1.06 (95% CI, 1.02–1.11); P = 0.003). Until now, stratification for severe lung hypoplasia has been based on an o/e‐LHR cut‐off of 45%. In cases managed expectantly, the survival rate was 15% (4/27) in those with o/e‐LHR ≤ 45% and 61% (36/59) for o/e‐LHR > 45% ( P = 0.001). However, the best o/e‐LHR cut‐off for the prediction of survival at discharge was 50%, with a sensitivity of 78% and specificity of 72%. In the expectantly managed group, survivors with severe pulmonary hypoplasia stayed longer in the neonatal intensive care unit than did those with mildly hypoplastic lungs. In fetuses with an o/e‐LHR ≤ 45% treated with FETO, survival rate was higher than in those with similar lung size managed expectantly (49/120 (41%) vs 4/27 (15%); P = 0.014), despite higher prematurity rates (gestational age at birth: 34.4 ± 2.7 weeks vs 36.8 ± 3.0 weeks; P < 0.0001). In fetuses treated with FETO, gestational age at birth was the only predictor of survival (OR, 1.25 (95% CI, 1.04–1.50); P = 0.02). Conclusions: Antenatal measurement of lung size can predict survival in iRCDH. In fetuses with severe lung hypoplasia, FETO was associated with a significant increase in survival without an associated increase in neonatal morbidity. © 2020 International Society of Ultrasound in Obstetrics and Gynecology
- 12 April 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 98 (9) , 1172-1177
Ventriculo‐amniotic shunting for severe fetal ventriculomegaly
Introduction: Severe fetal cerebral ventriculomegaly, observed in about 1 in 1000 newborns, is associated with a high risk of perinatal death and neurodevelopmental delay in survivors. The objective of this study was to evaluate the efficiency of ventriculo‐amniotic shunting for drainage of severe fetal cerebral ventriculomegaly and the neurodevelopment of survivors at the age of 2 years.Material and methods: This was a retrospective study of 44 fetuses with severe bilateral ventriculomegaly treated with ventriculo‐amniotic shunting in a tertiary fetal therapy center between 2010 and 2015.Results: Shunt insertion was successfully carried out at a median gestational age of 25 weeks (range 20‐33 weeks). There were three fetal deaths within 24 hours of the procedure and 41 live births at a median gestational age of 37 weeks (range 28‐39 weeks). Neurodevelopment at 2 years of age was evaluated using the Bayley scale in the 38 survivors. In the 27 cases with isolated ventriculomegaly 19 (70.4%; 95% confidence interval [95% CI] 51.5%‐84.2%) had normal or mild neurodevelopmental delay and 8 (29.6%; 95% CI 15.6%‐48.5%) were moderately or severely delayed. In the 11 with non‐isolated ventriculomegaly 2 (18.2%; 95% CI 5.1%‐4.8%) had normal or mild neurodevelopmental delay and 9 (81.8%; 95% CI 52.3%‐94.9%) babies were moderately or severely delayed.Conclusions: Ventriculo‐amniotic shunting is an option for the management of severe ventriculomegaly and results in normalization of the ventricular diameter. However, a high proportion of survivors have neurodevelopmental delay and the possible beneficial effect of ventriculo‐amniotic shunting needs to be assessed by randomized studies.
- 12 April 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 98 (9) , 1172-1177
Ventriculo‐amniotic shunting for severe fetal ventriculomegaly
Introduction: Severe fetal cerebral ventriculomegaly, observed in about 1 in 1000 newborns, is associated with a high risk of perinatal death and neurodevelopmental delay in survivors. The objective of this study was to evaluate the efficiency of ventriculo‐amniotic shunting for drainage of severe fetal cerebral ventriculomegaly and the neurodevelopment of survivors at the age of 2 years.Material and methods: This was a retrospective study of 44 fetuses with severe bilateral ventriculomegaly treated with ventriculo‐amniotic shunting in a tertiary fetal therapy center between 2010 and 2015.Results: Shunt insertion was successfully carried out at a median gestational age of 25 weeks (range 20‐33 weeks). There were three fetal deaths within 24 hours of the procedure and 41 live births at a median gestational age of 37 weeks (range 28‐39 weeks). Neurodevelopment at 2 years of age was evaluated using the Bayley scale in the 38 survivors. In the 27 cases with isolated ventriculomegaly 19 (70.4%; 95% confidence interval [95% CI] 51.5%‐84.2%) had normal or mild neurodevelopmental delay and 8 (29.6%; 95% CI 15.6%‐48.5%) were moderately or severely delayed. In the 11 with non‐isolated ventriculomegaly 2 (18.2%; 95% CI 5.1%‐4.8%) had normal or mild neurodevelopmental delay and 9 (81.8%; 95% CI 52.3%‐94.9%) babies were moderately or severely delayed.Conclusions: Ventriculo‐amniotic shunting is an option for the management of severe ventriculomegaly and results in normalization of the ventricular diameter. However, a high proportion of survivors have neurodevelopmental delay and the possible beneficial effect of ventriculo‐amniotic shunting needs to be assessed by randomized studies.